What data is needed to determine whether catheter closure of Fontan fenestration is of real incremental benefit to prevent ischemic stroke or TIA compared with oral anticoagulation therapy alone?
Currently, data on the efficacy and safety of DOACs to prevent recurrent thromboembolism in patients with congenital heart disease and history of ischemic stroke or TIA are limited to small observational series. Larger-scale multicenter observational data will be necessary to achieve adequate statistical power and to clarify whether DOACs can be used safely in patients with congenital heart disease.